Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
HNSCC
MCID: SQM013
MIFTS: 80

Squamous Cell Carcinoma, Head and Neck (HNSCC)

Categories: Cancer diseases, Gastrointestinal diseases, Genetic diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Squamous Cell Carcinoma, Head and Neck

About this section

MalaCards integrated aliases for Squamous Cell Carcinoma, Head and Neck:

Name: Squamous Cell Carcinoma, Head and Neck 56 13
Squamous Cell Carcinoma of the Head and Neck 12 52 25 73 29 6 15 71
Head and Neck Squamous Cell Carcinoma 12 52 25 15 17
Hnscc 56 52 25 73 54
Carcinoma, Squamous Cell of Head and Neck 74 52
Head and Neck Cancer 52 42
Squamous Cell Carcinoma of the Nasal Cavity and Paranasal Sinuses 58
Squamous Cell Carcinoma of the Nasal Cavity and Sinuses 58
Squamous Cell Carcinoma, Head and Neck, Somatic 56
Squamous Cell Carcinoma of the Hypopharynx 58
Squamous Cell Carcinoma of Salivary Glands 58
Squamous Cell Carcinoma of the Oral Cavity 58
Squamous Cell Carcinomas of Head and Neck 12
Squamous Cell Carcinoma of the Oropharynx 58
Carcinoma, Squamous Cell, Head and Neck 39
Salivary Gland Squamous Cell Carcinoma 17
Squamous Cell Carcinoma of the Larynx 58
Squamous Cell Carcinoma of the Lip 58
Carcinoma of the Head and Neck 12
Squamous Cell Carcinoma of Lip 71
Lip Squamous Cell Carcinoma 54
Cancer of Head and Neck 71
Cancer, Head/neck 39
Scchn 25

Characteristics:

OMIM:

56
Inheritance:
autosomal recessive


HPO:

31
squamous cell carcinoma, head and neck:
Inheritance autosomal recessive inheritance


Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases Cancer diseases
Anatomical: Gastrointestinal diseases
See all MalaCards categories (disease lists)
Orphanet: 58  
Rare gastroenterological diseases


External Ids:

Disease Ontology 12 DOID:5520
OMIM 56 275355
NCIt 49 C34447
MedGen 41 C1168401
SNOMED-CT via HPO 68 258211005 28899001 402815007
UMLS 71 C0278996 C0280302 C1168401
Sources

Summaries for Squamous Cell Carcinoma, Head and Neck

About this section
Genetics Home Reference : 25 Squamous cell carcinoma is a cancer that arises from particular cells called squamous cells. Squamous cells are found in the outer layer of skin and in the mucous membranes, which are the moist tissues that line body cavities such as the airways and intestines. Head and neck squamous cell carcinoma (HNSCC) develops in the mucous membranes of the mouth, nose, and throat. HNSCC is classified by its location: it can occur in the mouth (oral cavity), the middle part of the throat near the mouth (oropharynx), the space behind the nose (nasal cavity and paranasal sinuses), the upper part of the throat near the nasal cavity (nasopharynx), the voicebox (larynx), or the lower part of the throat near the larynx (hypopharynx). Depending on the location, the cancer can cause abnormal patches or open sores (ulcers) in the mouth and throat, unusual bleeding or pain in the mouth, sinus congestion that does not clear, sore throat, earache, pain when swallowing or difficulty swallowing, a hoarse voice, difficulty breathing, or enlarged lymph nodes. HNSCC can spread (metastasize) to other parts of the body, such as the lymph nodes or lungs. If it spreads, the cancer has a worse prognosis and can be fatal. About half of affected individuals survive more than five years after diagnosis.

MalaCards based summary : Squamous Cell Carcinoma, Head and Neck, also known as squamous cell carcinoma of the head and neck, is related to thyroid gland cancer and breast cancer, and has symptoms including tinnitus, halitosis and snoring. An important gene associated with Squamous Cell Carcinoma, Head and Neck is ING1 (Inhibitor Of Growth Family Member 1), and among its related pathways/superpathways are ERK Signaling and TGF-Beta Pathway. The drugs Epinephrine and Racepinephrine have been mentioned in the context of this disorder. Affiliated tissues include lung, lymph node and skin, and related phenotypes are squamous cell carcinoma and Decreased viability in esophageal squamous lineage

Disease Ontology : 12 A head and neck carcinoma that has material basis in squamous cells that line the moist, mucosal surfaces inside the head and neck.

NIH Rare Diseases : 52 Cancers that are known collectively as head and neck cancers usually begin in the squamous cells that line the moist, mucosal surfaces inside the head and neck (for example, inside the mouth, the nose, and the throat). These squamous cell cancers are often referred to as squamous cell carcinomas of the head and neck . At least 75 % of head and neck cancers are caused by tobacco and alcohol use. Infection with cancer-causing types of human papillomavirus (HPV), especially HPV-16, is a risk factor for some types of head and neck cancers. The symptoms of head and neck cancers may include a lump or a sore that does not heal, a sore throat that does not go away, difficulty in swallowing, and a change or hoarseness in the voice. Treatment for head and neck cancer can include surgery, radiation therapy , chemotherapy , targeted therapy, or a combination of treatments.

MedlinePlus : 42 Head and neck cancer includes cancers of the mouth, nose, sinuses, salivary glands, throat, and lymph nodes in the neck. Most begin in the moist tissues that line the mouth, nose, and throat. Symptoms include A lump or sore that does not heal A sore throat that does not go away Trouble swallowing A change or hoarseness in the voice Head and neck cancers are twice as common in men. Using tobacco or alcohol increases your risk. In fact, around 75 percent of head and neck cancers are linked to tobacco use, including smoking and smokeless tobacco. Infection with HPV is a risk factor for some head and neck cancers. To diagnose head and neck cancer, your doctor will do a physical exam and diagnostic tests. You will have a biopsy, where a sample of tissue is taken out and examined under a microscope. It is the only test that can tell for sure if you have cancer. If found early, these cancers are often curable. Treatments may include surgery, radiation therapy, chemotherapy, or a combination. Treatments can affect eating, speaking or even breathing, so patients may need rehabilitation. NIH: National Cancer Institute

UniProtKB/Swiss-Prot : 73 Squamous cell carcinoma of the head and neck: A non-melanoma skin cancer affecting the head and neck. The hallmark of cutaneous SCC is malignant transformation of normal epidermal keratinocytes.

Wikipedia : 74 Squamous cell carcinomas (SCCs), also known as epidermoid carcinomas, comprise a number of different... more...

More information from OMIM: 275355
Sources

Related Diseases for Squamous Cell Carcinoma, Head and Neck

About this section

Diseases related to Squamous Cell Carcinoma, Head and Neck via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 896)
# Related Disease Score Top Affiliating Genes
1 thyroid gland cancer 35.0 TP53 PTEN PIK3CA MIR21 MIR205 HRAS
2 breast cancer 33.6 TP53 TNFRSF10B SMAD4 PTEN PIK3CA MIR98
3 obsolete: squamous cell carcinoma of head and neck 33.6 TP53 TNFRSF10B SMAD4 PTEN PIK3CA NFE2L2
4 squamous cell carcinoma 33.5 TP53 TNFRSF10B SMAD4 PTEN PIK3CA NFE2L2
5 prostate cancer 33.2 TP53 TNFRSF10B SMAD4 PTEN PIK3CA NFE2L2
6 hepatocellular carcinoma 33.1 TP53 TNFRSF10B SMAD4 PTEN PIK3CA NFE2L2
7 colorectal cancer 33.1 TP53 TNFRSF10B SMAD4 PTEN PIK3CA NFE2L2
8 esophageal cancer 33.0 TP53 SMAD4 PTEN PIK3CA MIR21 MIR205
9 melanoma 32.9 TP53 TNFRSF10B PTEN PIK3CA MIR210 MIR205
10 lung cancer susceptibility 3 32.9 TP53 SMAD4 PTEN PIK3CA NFE2L2 MIR21
11 pancreatic cancer 32.9 TP53 TNFRSF10B SMAD4 PTEN PIK3CA MIR210
12 lung cancer 32.8 TP53 TNFRSF10B SMAD4 PTEN PIK3CA NFE2L2
13 glioblastoma multiforme 32.8 TP53 TNFRSF10B PTEN PIK3CA MIR210 MIR21
14 oral cavity cancer 32.8 TP53 TNFRSF10B PTEN PIK3CA MIR21 MIR205
15 cervical cancer 32.8 TP53 TNFRSF10B SMAD4 PTEN PIK3CA NFE2L2
16 bladder cancer 32.8 TP53 PTEN PIK3CA MIR21 MIR205 HRAS
17 lung squamous cell carcinoma 32.7 TP53 PTEN PIK3CA NFE2L2 HRAS FGFR3
18 gastric cancer 32.7 TP53 SMAD4 PTEN PIK3CA NFE2L2 MIR21
19 renal cell carcinoma, nonpapillary 32.6 TP53 TNFRSF10B PTEN PIK3CA MIR210 MIR21
20 adenocarcinoma 32.5 TP53 SMAD4 PTEN PIK3CA HRAS GNAS
21 glioma 32.5 TP53 PTEN PIK3CA MIR210 MIR21 IDH2
22 myeloma, multiple 32.5 TP53 TNFRSF10B PTEN MIR21 IDH2 HRAS
23 leukemia, acute myeloid 32.4 TP53 TNFRSF10B PTEN MIR210 MIR21 IDH2
24 ovarian cancer 32.4 TP53 TNFRSF10B SMAD4 PTEN PIK3CA MIR210
25 glioma susceptibility 1 32.3 TP53 PTEN PIK3CA MIR21 IDH2 HRAS
26 gastric adenocarcinoma 32.3 TP53 SMAD4 PTEN PIK3CA MAP2K2 HRAS
27 neuroblastoma 32.3 TP53 TNFRSF10B PTEN PIK3CA NFE2L2 MIR21
28 thyroid carcinoma 32.2 TP53 PTEN PIK3CA HRAS BRAF
29 retinitis pigmentosa 11 32.2 TP53 PTEN HRAS HOTAIR
30 in situ carcinoma 32.2 TP53 PTEN HRAS
31 nasopharyngeal carcinoma 32.1 TP53 SMAD4 PTEN PIK3CA MIR21 MIR205
32 oropharynx cancer 32.1 TP53 PTEN PIK3CA HRAS
33 adenoma 32.1 TP53 SMAD4 PIK3CA GNAS BRAF
34 oral squamous cell carcinoma 32.0 TP53 MIR21 MIR205 HRAS HOTAIR
35 adenosquamous carcinoma 32.0 TP53 SMAD4 PTEN PIK3CA
36 kidney cancer 32.0 TP53 PTEN PIK3CA NFE2L2 MIR210 MIR21
37 skin squamous cell carcinoma 32.0 TP53 PTEN HRAS BRAF
38 suppression of tumorigenicity 12 32.0 TP53 SMAD4 PTEN PIK3CA HRAS BRAF
39 skin melanoma 32.0 TP53 PTEN HRAS BRAF
40 carcinosarcoma 32.0 TP53 PTEN PIK3CA HRAS
41 endometrial cancer 31.9 TP53 SMAD4 PTEN PIK3CA HRAS HOTAIR
42 thyroid gland disease 31.9 TP53 PTEN MIR210 MIR21 MIR205 HRAS
43 thyroid tumor 31.9 TP53 PTEN PIK3CA HRAS BRAF
44 melanoma, cutaneous malignant 1 31.9 TP53 PTEN PIK3CA MAP2K2 HRAS BRAF
45 bladder urothelial carcinoma 31.9 TP53 PTEN PIK3CA NFE2L2 HRAS HOTAIR
46 malignant glioma 31.9 TP53 TNFRSF10B PTEN HOTAIR CYTOR
47 t-cell leukemia 31.8 TP53 SMAD4 PTEN PIK3CA HRAS
48 colon adenocarcinoma 31.8 TP53 SMAD4 PTEN PIK3CA MIR21
49 brain cancer 31.8 TP53 PTEN PIK3CA IDH2 HRAS BRAF
50 gastrointestinal stromal tumor 31.8 TP53 PTEN HOTAIR FGFR3 BRAF

Graphical network of the top 20 diseases related to Squamous Cell Carcinoma, Head and Neck:



Diseases related to Squamous Cell Carcinoma, Head and Neck
Sources

Symptoms & Phenotypes for Squamous Cell Carcinoma, Head and Neck

About this section

Human phenotypes related to Squamous Cell Carcinoma, Head and Neck:

31
# Description HPO Frequency HPO Source Accession
1 squamous cell carcinoma 31 HP:0002860

Symptoms via clinical synopsis from OMIM:

56
Lab:
beta family transforming growth factor resistance

Clinical features from OMIM:

275355

UMLS symptoms related to Squamous Cell Carcinoma, Head and Neck:


tinnitus, halitosis, snoring, sore throat, coughing, vertigo/dizziness, equilibration disorder

GenomeRNAi Phenotypes related to Squamous Cell Carcinoma, Head and Neck according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability in esophageal squamous lineage GR00235-A 9.7 BRAF FGFR3 GNAS HRAS IDH2 ING1
2 Decreased cell migration GR00055-A-1 9.65 BRAF FGFR3 HRAS MAP2K2 PIK3CA
3 Reduced mammosphere formation GR00396-S 9.17 BRAF GNAS HRAS IDH2 NFE2L2 PTEN
4 Decreased sensitivity to paclitaxel GR00112-A-0 9.16 PTEN SMAD4

MGI Mouse Phenotypes related to Squamous Cell Carcinoma, Head and Neck:

45 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.18 BRAF GNAS HRAS IDH2 MAP2K2 NFE2L2
2 integument MP:0010771 10.07 BRAF FGFR3 GNAS HRAS MAP2K2 NFE2L2
3 craniofacial MP:0005382 10.06 BRAF FGFR3 GNAS HRAS MAP2K2 NFE2L2
4 endocrine/exocrine gland MP:0005379 10.06 BRAF GNAS HRAS ING1 MAP2K2 PIK3CA
5 adipose tissue MP:0005375 10.04 BRAF GNAS MAP2K2 NFE2L2 PIK3CA PTEN
6 digestive/alimentary MP:0005381 10.03 BRAF FGFR3 HRAS MAP2K2 NFE2L2 PTEN
7 neoplasm MP:0002006 10.03 BRAF FGFR3 GNAS HRAS IDH2 ING1
8 limbs/digits/tail MP:0005371 9.87 BRAF FGFR3 GNAS IDH2 PTEN SMAD4
9 normal MP:0002873 9.81 BRAF FGFR3 GNAS HRAS MAP2K2 NFE2L2
10 renal/urinary system MP:0005367 9.56 BRAF FGFR3 GNAS HRAS NFE2L2 PTEN
11 skeleton MP:0005390 9.36 BRAF FGFR3 GNAS HRAS IDH2 MAP2K2
Sources

Drugs & Therapeutics for Squamous Cell Carcinoma, Head and Neck

About this section

Drugs for Squamous Cell Carcinoma, Head and Neck (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 666)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
2
Racepinephrine Approved Phase 4 329-65-7 838
3
Cevimeline Approved Phase 4 107233-08-9 83898 25137844
4
Norepinephrine Approved Phase 4 51-41-2 439260
5
Methadone Approved Phase 4 76-99-3 4095
6
Citalopram Approved Phase 4 59729-33-8 2771
7
Dobutamine Approved Phase 4 34368-04-2 36811
8
Meperidine Approved Phase 4 57-42-1 4058
9
Dopexamine Approved, Investigational Phase 4 86197-47-9 55483
10
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
11
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
12
Hydrocodone Approved, Illicit, Investigational Phase 4 125-29-1 5284569
13
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
14
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
15
Levobupivacaine Approved, Investigational Phase 4 27262-47-1 92253
16
Nicotine Approved Phase 4 54-11-5 942 89594
17
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
18
Acetaminophen Approved Phase 4 103-90-2 1983
19
Morphine Approved, Investigational Phase 4 57-27-2 5288826
20
Tyrosine Approved, Investigational, Nutraceutical Phase 4 60-18-4 6057
21 Sympathomimetics Phase 4
22 Epinephryl borate Phase 4
23 Anti-Asthmatic Agents Phase 4
24 Vasoconstrictor Agents Phase 4
25 Adrenergic Agonists Phase 4
26 Bronchodilator Agents Phase 4
27 Adrenergic beta-Agonists Phase 4
28 Mydriatics Phase 4
29 Adrenergic Agents Phase 4
30 Muscarinic Agonists Phase 4
31 Serotonin Uptake Inhibitors Phase 4
32 Muscarinic Antagonists Phase 4
33 Cholinergic Antagonists Phase 4
34 Parasympatholytics Phase 4
35 Dopamine agonists Phase 4
36 Antipyretics Phase 4
37 Respiratory System Agents Phase 4
38 Anesthetics Phase 4
39 Psychotropic Drugs Phase 4
40 Narcotics Phase 4
41 Anesthetics, General Phase 4
42 Analgesics, Opioid Phase 4
43 Anesthetics, Intravenous Phase 4
44 Tranquilizing Agents Phase 4
45 Anti-Anxiety Agents Phase 4
46 Anticonvulsants Phase 4
47 Antitussive Agents Phase 4
48 Chlorpheniramine, phenylpropanolamine drug combination Phase 4
49 Antimanic Agents Phase 4
50 Excitatory Amino Acids Phase 4

Interventional clinical trials:

(show top 50) (show all 2408)
# Name Status NCT ID Phase Drugs
1 Skin Changes in Head and Neck Cancer During Immuno-(Chemo-) And Radiotherapy With Erbitux® Unknown status NCT01553032 Phase 4 Erbitux®
2 Randomized Phase IV Trial to Compare Cetuximab With Concomitant Radiation Therapy With Concomitant Mitomycin-C and 5-Fluorouracil With Radiation Therapy for Locally Advanced Squamous Cell Carcinomas of the Head and Neck Unknown status NCT02015650 Phase 4 Cetuximab;Mitomycin-C/ 5-Fluorouracil
3 EVALUATION OF THE USE OF N-ACETYLCYSTEINE ATTENUATING CISPLATIN-INDUCED TOXICITIES BY OXIDATIVE STRESS IN HEAD AND NECK CANCER PATIENTS Unknown status NCT02241876 Phase 4 N-acetylcysteine
4 Effectiveness of Low Energy Laser Treatment in Oral Mucositis Induced by Chemotherapy and Radiotherapy in Head and Neck Cancer Unknown status NCT01876407 Phase 4
5 Pharmacokinetics and Pharmacogenetics-based Adaptive Dosing of 5-fu (5-Fluorouracile) in Head & Neck Cancer Patient Undergoing Docetaxel, Cisplatin, 5-Fluorouracile (=TPF) Therapy Unknown status NCT02484677 Phase 4 Cisplatin;Docetaxel;5-Fluorouracile
6 Open-Label, Multi-Center, Randomized, Active-Controlled, Phase 4 Study of rAd-p53 Gene Therapy Combined With Chemotherapy and Radiotherapy in Treament of Head and Neck Cancer in Advanced Stage Unknown status NCT00894153 Phase 4 chemotherapy plus p53;chemotherapy
7 A Randomized Study on the Effects of Lactobacillus Brevis CD2 in the Prevention of Radio and Chemotherapy Induced Oral Mucositis in Head and Neck Cancer Patients. Unknown status NCT01707641 Phase 4
8 Comparison Between Two Regimens of Chemotherapy Concurrent With Radiotherapy in Locally Advanced Head and Neck Cancer Completed NCT03998696 Phase 4 Cisplatin 40 mg/m2;Cisplatin 100 mg/m2
9 Phase IV Trial to Use Stereotactic Body Radiotherapy for Head and Neck Tumors Completed NCT01344356 Phase 4
10 An Investigator-Initiated,Multicenter,Randomized,Double-Blind Placebo-Controlled Design Study to Assess the Effectiveness of CeviMeline to Improve OraL Health in Patients With XErostomia Secondary to Radiation Therapy for Treatment of Head and Neck Squamous Cell Carcinoma Completed NCT00466388 Phase 4 Cevimeline
11 An Open-Label Study Using the Medpulser® Electroporation System to Treat Head and Neck Cancer Completed NCT00198263 Phase 4
12 Treatment of Pain in Head-and-Neck Cancer Patients: is Methadone More Effective Than Fentanyl? Completed NCT01317589 Phase 4 fentanyl;methadone
13 Prevention of Depression in Patients Being Treated for Head and Neck Cancer Completed NCT00536172 Phase 4 Escitalopram;Placebo
14 The Multi-center,Open-label,Single Arm Phase IV Clinical Trial of Efficacy and Safety of PEG-rhG-CSF in Patients With Lung Cancer,Head and Neck Cancer,Colorectal Cancer,Ovarian Cancer and the Other Cancer Receiving Chemotherapy Completed NCT02805166 Phase 4 PEG-rhG-CSF
15 The Effect of Norepinephrine and Dopamine on Radial Forearm Free Flap Tissue Oxygen Pressure and Microdialysate Metabolite Measurements Completed NCT02241083 Phase 4 Dopamine;Norepinephrine
16 A Randomized, Double-blind Study to Evaluate the Efficacy of MuGard Mucoadhesive Oral Wound Rinse for the Amelioration of Oral Mucositis in Subjects Receiving Chemoradiation Therapy for the Treatment of Cancers of the Head and Neck Completed NCT01283906 Phase 4
17 Clinical Evaluation of a Salivary Substitute and a Mucoprotective Product on Xerostomia in Head-and-neck Cancer Patients Completed NCT01316393 Phase 4
18 A Prospective Randomized Study of LigaSure Small Jaw® Versus Conventional Neck Dissection in Head and Neck Cancer Patients Completed NCT02597582 Phase 4
19 Open-Label Prospective Trial Evaluating the Toxicities Associated With Subcutaneous Administration of Ethyol (Amifostine) for the Prevention of Radiation-Induced Toxicities Completed NCT00158041 Phase 4 Amifostine administered subcutaneously
20 Effect of Enteral Immunonutrition During Chemoradiotherapy in Patients With Head and Neck Cancer or Esophageal Cancer Completed NCT00333099 Phase 4
21 A Clinical Trial of ALA Photodynamic Therapy for Treatment of Actinic Cheilitis in Patients With Squamous Cell Carcinoma of the Lip. Completed NCT00868088 Phase 4
22 Preloading Magnesium Attenuate Cisplatin-induced Nephrotoxicity Completed NCT02481518 Phase 4 Magnesium
23 Perioperative Gabapentin Use In Head And Neck Mucosal Surgery Patients: A Randomized Clinical Trial Completed NCT02926573 Phase 4 Gabapentin;Placebo
24 An Assessment of the Effects of Pressors on Graft Blood Flow After Free Tissue Transfer Surgery: A Randomised Study Completed NCT01418118 Phase 4 Epinephrine;Norepinephrine;Dobutamine;Dopexamine
25 Advances in the Management of Mandibular Osteoradionecrosis: Pentoxifylline and Tocopherol as Medical Treatment Completed NCT02368457 Phase 4 Pentoxifylline and Tocopherol
26 Absorption of Orally Ingested Phosphate in Head and Neck Cancer Patients With and Without Refeeding Syndrome Completed NCT02880072 Phase 4
27 Radiotherapy Combine With Raltitrexed Versus Radiotherapy Alone in Older Patients With Head and Neck Squamous Cell Carcinoma: a Prospective Randomized Controlled Trial Recruiting NCT03196843 Phase 4 Raltitrexed
28 Clinical Study of the Effects of Compound Kushen Injection on Radiation-induced Oral Mucositis in Head and Neck Cancer Patients. Recruiting NCT04204382 Phase 4 Levofloxacin injection;Compound kushen injection
29 Does Continuous Popliteal Nerve Block Improve Pain Management for Patients Undergoing Major Maxilla or Mandible Resection With Microvascular Reconstruction Using a Free Fibula Graft Recruiting NCT03607227 Phase 4 Levobupivacaine;Saline Solution
30 A Randomized Placebo-controlled Pilot Study of Single-dose Intraoperative Ketamine for the Prevention of Delirium in Otolaryngeal Cancer Surgery Patients Recruiting NCT03040024 Phase 4 Ketamine;Placebo
31 Pain Management in Head and Neck Surgery Patients Recruiting NCT03121963 Phase 4 Oxycodone;Acetaminophen;Gabapentin;Celecoxib;Hydrocodone-Acetaminophen
32 Implementation Strategies to Improve Tobacco Treatment for UF Health Cancer Center Patients Active, not recruiting NCT03482583 Phase 4 Nicotine Replacement Therapy
33 Use of Single Dose Pre-Operative Pregabalin for Post-Operative Analgesia in Bilateral Head and Neck Cancer Surgery: A Randomized, Double-Blinded, Placebo-Controlled Trial Enrolling by invitation NCT03714867 Phase 4 Pregabalin 150mg
34 A Single Arm, Multi-center Study to Assess the Efficacy and Safety of Docetaxel Combined With Carboplatin Plus Anlotinib as First Line Treatment in Non-squamous Non-small-cell Lung Cancer (NSCLC) Not yet recruiting NCT03799601 Phase 4 Anlotinib;Docetaxel;Carboplatin
35 Prospective, Open-label, Randomized, Control Study of Head and Neck Cancer Radiation Treatment With or Without Amifostine Suspended NCT01288625 Phase 4 Amifostine
36 Determination of the Optimal Infusion Rate of Amino Acids in Seriously Ill Patients Terminated NCT01923480 Phase 4 15% CLINISOL - Sulfite-free (Amino Acid) Injection;15% CLINISOL - Sulfite-free (Amino Acid) Injection;15% CLINISOL - Sulfite-free (Amino Acid) Injection
37 Radiotherapy Dose Escalation in Locally Advanced Squamous Cell Carcinoma of the Larynx or Hypopharynx Withdrawn NCT03388931 Phase 4
38 Phase II GENIUS Trial of GENetically-Informed Therapies for Patients With previoUSly Treated Refractory Metastatic Cancer Withdrawn NCT02000739 Phase 4
39 Controlled Randomized Trial to Evaluate Efficacy of Adjuvant Chemotherapy Between S-1 and UFT for Locally Advanced Squamous Cell Carcinoma of the Head and Neck: Phase III Study Unknown status NCT00336947 Phase 3 tegafur-gimeracil-oteracil potassium;tegafur-uracil
40 A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFECT OF CISPLATIN/EPINEPHRINE INJECTABLE GEL (PRODUCT MPI 5010) WHEN ADMINISTERED INTRATUMORALLY FOR ACHIEVEMENT OF TREATMENT GOALS IN RECURRENT OR REFRACTORY SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK Unknown status NCT00002659 Phase 3 cisplatin-e therapeutic implant
41 A Multi-centre Randomised Phase III Trial Comparing PET-CT Guided Watch and Wait Policy Versus Planned Neck Dissection for the Management of Locally Advanced (N2/N3) Nodal Metastases in Patients With Head and Neck Squamous Cancer Unknown status NCT00720070 Phase 3
42 A Phase III Trial of Concurrent Radiation and Chemotherapy for Advanced Head and Neck Carcinomas Unknown status NCT00047008 Phase 3 cisplatin
43 Multicentre Randomised Trial of Inductive and Adjuvant Perilymphatically Injected Proleukin (rlL-2) in The Treatment of Operable Primary Squamous Cell Carcinoma of The Oral Cavity and Oropharynx Unknown status NCT00002702 Phase 3
44 A Randomized, Open-label, Multi-center Phase III Study Designed to Evaluate the Safety and Efficacy of E10A in Patients With Recurrent/Unresectable Squamous Cell Carcinoma of the Head and Neck Region Unknown status NCT02630264 Phase 3 Endostatins;Paclitaxel injection;Cisplatin injection
45 DAHANCA 30: A Randomized Non-inferiority Trial of Hypoxia-profile Guided Hypoxic Modification With Nimorazole During Radiotherapy/Chemoradiotherapy of Squamous Cell Carcinoma of the Head and Neck. Unknown status NCT02661152 Phase 3 Nimorazole
46 A Multicentre Randomised Study Of Parotid Sparing Intensity Modulated Radiotherapy Versus Conventional Radiotherapy In Patients With Head And Neck Cancer Unknown status NCT00081029 Phase 3
47 RANDOMIZED TRIAL OF NEOADJUVANT CHEMOTHERAPY AND SURGERY +/- RADIOTHERAPY VERSUS SURGEERY +/- RADIOTHERAPY IN OPERABLE SQUAMOUS CELL CARCINOMA OF THE ORAL CAVITY Unknown status NCT00002747 Phase 3 cisplatin;fluorouracil
48 Effectiveness and Safety of INGN 201 in Combination With Chemotherapy Versus Chemotherapy Alone Unknown status NCT00041626 Phase 3
49 Study to Compare the Overall Survival of Patients Receiving INGN 201 (Study Drug) With Patients Receiving Methotrexate Unknown status NCT00041613 Phase 3
50 Phase III Randomized Study of Radiotherapy With or Without Cisplatin and Fluorouracil for Locally Advanced, Nonresectable Squamous Cell Cancer of the Oropharynx or Hypopharynx Unknown status NCT00003627 Phase 3 cisplatin;fluorouracil

Search NIH Clinical Center for Squamous Cell Carcinoma, Head and Neck

Sources

Genetic Tests for Squamous Cell Carcinoma, Head and Neck

About this section

Genetic tests related to Squamous Cell Carcinoma, Head and Neck:

# Genetic test Affiliating Genes
1 Squamous Cell Carcinoma of the Head and Neck 29 ING1 TNFRSF10B
Sources

Anatomical Context for Squamous Cell Carcinoma, Head and Neck

About this section

MalaCards organs/tissues related to Squamous Cell Carcinoma, Head and Neck:

40
Lung, Lymph Node, Skin, Salivary Gland, Thyroid, T Cells, Breast
Sources

Publications for Squamous Cell Carcinoma, Head and Neck

About this section

Articles related to Squamous Cell Carcinoma, Head and Neck:

(show top 50) (show all 4505)
# Title Authors PMID Year
1
Detection of new PTEN/MMAC1 mutations in head and neck squamous cell carcinomas with loss of chromosome 10. 56 6
11801303 2002
2
Genomic structure of the human ING1 gene and tumor-specific mutations detected in head and neck squamous cell carcinomas. 56 6
10866301 2000
3
Rare loss-of-function mutation of a death receptor gene in head and neck cancer. 56 6
9721851 1998
4
Comprehensive genomic characterization of head and neck squamous cell carcinomas. 56
25631445 2015
5
The mutational landscape of head and neck squamous cell carcinoma. 56
21798893 2011
6
Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. 56
21798897 2011
7
Network modeling identifies molecular functions targeted by miR-204 to suppress head and neck tumor metastasis. 61 46
20369013 2010
8
Identification of a microRNA signature associated with progression of leukoplakia to oral carcinoma. 56
19776030 2009
9
An expression profile for diagnosis of lymph node metastases from primary head and neck squamous cell carcinomas. 56
15640797 2005
10
Defects in cell growth regulation by C18:0-ceramide and longevity assurance gene 1 in human head and neck squamous cell carcinomas. 56
15317812 2004
11
Functional evidence for a squamous cell carcinoma mortality gene(s) on human chromosome 4. 56
12140764 2002
12
Microsatellite alterations in serum DNA of head and neck cancer patients. 56
8782464 1996
13
Resistance of human squamous carcinoma cells to transforming growth factor beta 1 is a recessive trait. 56
8327510 1993
14
A systematic review and meta-analysis approach on diagnostic value of MLH1 promoter methylation for head and neck squamous cell carcinoma. 42
31651887 2019
15
Hypoxia with 18F-fluoroerythronitroimidazole integrated positron emission tomography and computed tomography (18F-FETNIM PET/CT) in locoregionally advanced head and neck cancer: Hypoxia changes during chemoradiotherapy and impact on clinical outcome. 42
31577699 2019
16
Associations between FDG-PET and Ki 67-index in head and neck cancer: A meta-analysis. 42
31577779 2019
17
New strategies in head and neck cancer: understanding resistance to epidermal growth factor receptor inhibitors. 54 61
20406834 2010
18
Hypoxia-inducible mir-210 regulates normoxic gene expression involved in tumor initiation. 46
19782034 2009
19
MicroRNA expression ratio is predictive of head and neck squamous cell carcinoma. 46
19351747 2009
20
Bcl-2 blocks cisplatin-induced apoptosis and predicts poor outcome following chemoradiation treatment in advanced oropharyngeal squamous cell carcinoma. 54 61
19240170 2009
21
Low-level expression of microRNAs let-7d and miR-205 are prognostic markers of head and neck squamous cell carcinoma. 46
19179615 2009
22
Genetic polymorphisms in DNA base excision repair gene XRCC1 and the risk of squamous cell carcinoma of the head and neck. 54 61
19284666 2009
23
Detection of metastatic head and neck squamous cell carcinoma using the relative expression of tissue-specific mir-205. 46
19043531 2008
24
MicroRNA alterations in head and neck squamous cell carcinoma. 46
18798260 2008
25
The role of cetuximab for the treatment of squamous cell carcinoma of the head and neck. 54 61
18997665 2008
26
Identification of the rare EGFR mutation p.G796S as somatic and germline mutation in white patients with squamous cell carcinoma of the head and neck. 54 61
18528899 2008
27
A genotype-phenotype examination of cyclin D1 on risk and outcome of squamous cell carcinoma of the head and neck. 54 61
18413827 2008
28
Inverse relationship between human papillomavirus-16 infection and disruptive p53 gene mutations in squamous cell carcinoma of the head and neck. 54 61
18223210 2008
29
STAT3 signaling is induced by intercellular adhesion in squamous cell carcinoma cells. 54 61
17961551 2008
30
The role of genetic factor in etiopathogenesis of squamous cell carcinoma of the head and neck in young adults. 54 61
17653748 2007
31
P53 codon 72 polymorphism in squamous cell carcinoma of the head and neck region. 54 61
17970074 2007
32
MicroRNA expression profiles in head and neck cancer cell lines. 46
17475218 2007
33
Loss of p53 expression correlates with metastatic phenotype and transcriptional profile in a new mouse model of head and neck cancer. 54 61
17426250 2007
34
Detection of human papillomavirus-16 in fine-needle aspirates to determine tumor origin in patients with metastatic squamous cell carcinoma of the head and neck. 54 61
17317828 2007
35
EGFR mutations and human papillomavirus in squamous cell carcinoma of tongue and tonsil. 54 61
17224267 2007
36
High mobility group A2 is a target for miRNA-98 in head and neck squamous cell carcinoma. 46
17222355 2007
37
EphB4 provides survival advantage to squamous cell carcinoma of the head and neck. 54 61
16615113 2006
38
Fine-mapping loss of gene architecture at the CDKN2B (p15INK4b), CDKN2A (p14ARF, p16INK4a), and MTAP genes in head and neck squamous cell carcinoma. 54 61
16618910 2006
39
Combination chemotherapy and radiation of human squamous cell carcinoma of the head and neck augments CTL-mediated lysis. 54 61
16551875 2006
40
Association between high collagenase-3 expression levels and poor prognosis in patients with head and neck cancer. 54 61
16302191 2006
41
SOCS-3 is frequently methylated in head and neck squamous cell carcinoma and its precursor lesions and causes growth inhibition. 54 61
16007169 2005
42
A study of TRAIL receptors in squamous cell carcinoma of the head and neck. 54 61
15897419 2005
43
The effect of tetrathiomolybdate on cytokine expression, angiogenesis, and tumor growth in squamous cell carcinoma of the head and neck. 54 61
15781759 2005
44
Real-time expression profiling of microRNA precursors in human cancer cell lines. 46
16192569 2005
45
Function and importance of p63 in normal oral mucosa and squamous cell carcinoma of the head and neck. 54 61
15608417 2005
46
Chemokine receptors 6 and 7 identify a metastatic expression pattern in squamous cell carcinoma of the head and neck. 54 61
15608423 2005
47
Phase II trial of cisplatin and capecitabine in patients with squamous cell carcinoma of the head and neck, and correlative study of angiogenic factors. 54 61
15597103 2004
48
Expression of c-erbB receptors, MMPs and VEGF in squamous cell carcinoma of the head and neck. 54 61
15254682 2004
49
Identification of a gene expression signature associated with recurrent disease in squamous cell carcinoma of the head and neck. 54 61
14729608 2004
50
Polymorphisms of GSTT1 and related genes in head and neck cancer risk. 54 61
14724908 2004
Sources

Variations for Squamous Cell Carcinoma, Head and Neck

About this section

ClinVar genetic disease variations for Squamous Cell Carcinoma, Head and Neck:

6 (show top 50) (show all 383) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 EGFR NM_005228.5(EGFR):c.2155G>C (p.Gly719Arg)SNV Likely pathogenic,drug response 45224 rs28929495 7:55241707-55241707 7:55174014-55174014
2 TP53 NM_000546.5(TP53):c.832C>A (p.Pro278Thr)SNV Likely pathogenic,drug response 376643 rs17849781 17:7577106-7577106 17:7673788-7673788
3 TP53 NM_000546.5(TP53):c.537T>G (p.His179Gln)SNV Pathogenic 376607 rs876660821 17:7578393-7578393 17:7675075-7675075
4 TP53 NM_000546.5(TP53):c.578A>C (p.His193Pro)SNV Pathogenic 376612 rs786201838 17:7578271-7578271 17:7674953-7674953
5 TP53 NM_000546.5(TP53):c.713G>T (p.Cys238Phe)SNV Pathogenic 376574 rs730882005 17:7577568-7577568 17:7674250-7674250
6 TP53 NM_000546.5(TP53):c.712T>C (p.Cys238Arg)SNV Pathogenic 376576 rs1057519981 17:7577569-7577569 17:7674251-7674251
7 TP53 NM_000546.5(TP53):c.841G>T (p.Asp281Tyr)SNV Pathogenic 376585 rs764146326 17:7577097-7577097 17:7673779-7673779
8 TP53 NM_000546.5(TP53):c.841G>A (p.Asp281Asn)SNV Pathogenic 376586 rs764146326 17:7577097-7577097 17:7673779-7673779
9 PIK3CA NM_006218.4(PIK3CA):c.1357G>A (p.Glu453Lys)SNV Pathogenic 376470 rs1057519925 3:178928079-178928079 3:179210291-179210291
10 PIK3CA NM_006218.4(PIK3CA):c.2176G>A (p.Glu726Lys)SNV Pathogenic 376476 rs867262025 3:178938934-178938934 3:179221146-179221146
11 PIK3CA NM_006218.4(PIK3CA):c.1637A>G (p.Gln546Arg)SNV Pathogenic 45466 rs397517201 3:178936095-178936095 3:179218307-179218307
12 PIK3CA NM_006218.4(PIK3CA):c.3139C>T (p.His1047Tyr)SNV Pathogenic 39705 rs121913281 3:178952084-178952084 3:179234296-179234296
13 TP53 NM_000546.5(TP53):c.659A>G (p.Tyr220Cys)SNV Pathogenic 127819 rs121912666 17:7578190-7578190 17:7674872-7674872
14 TP53 NM_000546.5(TP53):c.488A>G (p.Tyr163Cys)SNV Pathogenic 127814 rs148924904 17:7578442-7578442 17:7675124-7675124
15 TP53 NM_000546.5(TP53):c.422G>A (p.Cys141Tyr)SNV Pathogenic 140801 rs587781288 17:7578508-7578508 17:7675190-7675190
16 TP53 NM_000546.5(TP53):c.844C>G (p.Arg282Gly)SNV Pathogenic 140821 rs28934574 17:7577094-7577094 17:7673776-7673776
17 TP53 NM_000546.5(TP53):c.638G>A (p.Arg213Gln)SNV Pathogenic 135359 rs587778720 17:7578211-7578211 17:7674893-7674893
18 TP53 NM_000546.5(TP53):c.842A>G (p.Asp281Gly)SNV Pathogenic 141141 rs587781525 17:7577096-7577096 17:7673778-7673778
19 TP53 NM_000546.5(TP53):c.706T>G (p.Tyr236Asp)SNV Pathogenic 142183 rs587782289 17:7577575-7577575 17:7674257-7674257
20 TP53 NM_000546.5(TP53):c.833C>T (p.Pro278Leu)SNV Pathogenic 232497 rs876659802 17:7577105-7577105 17:7673787-7673787
21 TP53 NM_000546.5(TP53):c.743G>T (p.Arg248Leu)SNV Pathogenic 230253 rs11540652 17:7577538-7577538 17:7674220-7674220
22 PTEN NM_001304718.2(PTEN):c.-363C>GSNV Pathogenic 375958 rs121909224 10:89692904-89692904 10:87933147-87933147
23 TP53 NM_000546.5(TP53):c.856G>A (p.Glu286Lys)SNV Pathogenic 183752 rs786201059 17:7577082-7577082 17:7673764-7673764
24 TNFRSF10B TNFRSF10B, 2-BP INSinsertion Pathogenic 6194
25 PTEN NM_000314.7(PTEN):c.389G>A (p.Arg130Gln)SNV Pathogenic 7829 rs121909229 10:89692905-89692905 10:87933148-87933148
26 PTEN NM_001304718.2(PTEN):c.-389C>GSNV Pathogenic 7842 rs121909237 10:89692878-89692878 10:87933121-87933121
27 ING1 NM_198219.3(ING1):c.644G>C (p.Cys215Ser)SNV Pathogenic 8067 rs121909250 13:111372083-111372083 13:110719736-110719736
28 ING1 NM_198219.3(ING1):c.647A>G (p.Asn216Ser)SNV Pathogenic 8068 rs121909251 13:111372086-111372086 13:110719739-110719739
29 ING1 NM_198219.3(ING1):c.575C>A (p.Ala192Asp)SNV Pathogenic 8069 rs121909252 13:111372014-111372014 13:110719667-110719667
30 MAP2K2 NM_030662.3(MAP2K2):c.169T>G (p.Phe57Val)SNV Pathogenic 8273 rs121434498 19:4117551-4117551 19:4117553-4117553
31 SMAD4 NM_005359.5(SMAD4):c.1081C>T (p.Arg361Cys)SNV Pathogenic 8543 rs80338963 18:48591918-48591918 18:51065548-51065548
32 TP53 NM_000546.5(TP53):c.742C>T (p.Arg248Trp)SNV Pathogenic 12347 rs121912651 17:7577539-7577539 17:7674221-7674221
33 TP53 NM_000546.5(TP53):c.733G>T (p.Gly245Cys)SNV Pathogenic 12349 rs28934575 17:7577548-7577548 17:7674230-7674230
34 TP53 NM_000546.5(TP53):c.725G>A (p.Cys242Tyr)SNV Pathogenic 12354 rs121912655 17:7577556-7577556 17:7674238-7674238
35 TP53 NM_000546.5(TP53):c.584T>C (p.Ile195Thr)SNV Pathogenic 216077 rs760043106 17:7578265-7578265 17:7674947-7674947
36 TP53 NM_000546.5(TP53):c.517G>A (p.Val173Met)SNV Pathogenic 233951 rs876660754 17:7578413-7578413 17:7675095-7675095
37 TP53 NM_000546.5(TP53):c.743G>A (p.Arg248Gln)SNV Pathogenic 12356 rs11540652 17:7577538-7577538 17:7674220-7674220
38 TP53 NM_000546.5(TP53):c.1010G>A (p.Arg337His)SNV Pathogenic 12379 rs121912664 17:7574017-7574017 17:7670699-7670699
39 TP53 NM_000546.5(TP53):c.659A>C (p.Tyr220Ser)SNV Pathogenic 12383 rs121912666 17:7578190-7578190 17:7674872-7674872
40 HRAS NM_005343.4(HRAS):c.34G>A (p.Gly12Ser)SNV Pathogenic 12602 rs104894229 11:534289-534289 11:534289-534289
41 HRAS NM_005343.4(HRAS):c.35G>C (p.Gly12Ala)SNV Pathogenic 12603 rs104894230 11:534288-534288 11:534288-534288
42 HRAS NM_005343.4(HRAS):c.37G>T (p.Gly13Cys)SNV Pathogenic 12606 rs104894228 11:534286-534286 11:534286-534286
43 HRAS NM_005343.4(HRAS):c.34G>T (p.Gly12Cys)SNV Pathogenic 12613 rs104894229 11:534289-534289 11:534289-534289
44 PIK3CA NM_006218.4(PIK3CA):c.3140A>G (p.His1047Arg)SNV Pathogenic 13652 rs121913279 3:178952085-178952085 3:179234297-179234297
45 PIK3CA NM_006218.4(PIK3CA):c.3140A>T (p.His1047Leu)SNV Pathogenic 13653 rs121913279 3:178952085-178952085 3:179234297-179234297
46 TP53 NM_000546.5(TP53):c.733G>A (p.Gly245Ser)SNV Pathogenic 12365 rs28934575 17:7577548-7577548 17:7674230-7674230
47 TP53 NM_000546.5(TP53):c.818G>A (p.Arg273His)SNV Pathogenic 12366 rs28934576 17:7577120-7577120 17:7673802-7673802
48 PIK3CA NM_006218.4(PIK3CA):c.1634A>C (p.Glu545Ala)SNV Pathogenic 13659 rs121913274 3:178936092-178936092 3:179218304-179218304
49 BRAF NM_004333.6(BRAF):c.1799T>A (p.Val600Glu)SNV Pathogenic 13961 rs113488022 7:140453136-140453136 7:140753336-140753336
50 BRAF NM_004333.6(BRAF):c.1781A>G (p.Asp594Gly)SNV Pathogenic 13972 rs121913338 7:140453154-140453154 7:140753354-140753354

UniProtKB/Swiss-Prot genetic disease variations for Squamous Cell Carcinoma, Head and Neck:

73
# Symbol AA change Variation ID SNP ID
1 ING1 p.Ala335Asp VAR_017420
2 ING1 p.Cys358Ser VAR_017421
3 ING1 p.Asn359Ser VAR_017422
4 ING3 p.Asp20Gly VAR_021263
5 PTEN p.Ala121Gly VAR_018103 rs121909237

Cosmic variations for Squamous Cell Carcinoma, Head and Neck:

9 (show top 50) (show all 822)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM87898351 TP53 skin,neck,carcinoma,squamous cell carcinoma c.743G>A p.R248Q 17:7674220-7674220 12
2 COSM135128838 TGFBR1 skin,neck,carcinoma,squamous cell carcinoma c.1259C>T p.S420F 9:99146601-99146601 12
3 COSM84678061 SMO skin,neck,carcinoma,squamous cell carcinoma c.1103C>T p.P368L 7:129206332-129206332 12
4 COSM86828717 RARA skin,neck,carcinoma,squamous cell carcinoma c.1384C>T p.P462S 17:40356221-40356221 12
5 COSM94496058 RAD52 skin,neck,carcinoma,squamous cell carcinoma c.439G>A p.V147M 12:927173-927173 12
6 COSM97061657 PTPRT skin,neck,carcinoma,squamous cell carcinoma c.1619G>A p.G540E 20:42352227-42352227 12
7 COSM97061670 PTPRT skin,neck,carcinoma,squamous cell carcinoma c.1607C>T p.S536L 20:42352239-42352239 12
8 COSM101904169 PTPRD skin,neck,carcinoma,squamous cell carcinoma c.1261C>T p.P421S 9:8518130-8518130 12
9 COSM101917565 PTPRD skin,neck,carcinoma,squamous cell carcinoma c.1736G>A p.S579N 9:8504347-8504347 12
10 COSM101909541 PTPRD skin,neck,carcinoma,squamous cell carcinoma c.5048C>T p.S1683F 9:8341168-8341168 12
11 COSM135344063 PLCG2 skin,neck,carcinoma,squamous cell carcinoma c.115G>T p.E39* 16:81786104-81786104 12
12 COSM96446251 PIK3CG skin,neck,carcinoma,squamous cell carcinoma c.310G>A p.G104R 7:106867871-106867871 12
13 COSM96446257 PIK3CG skin,neck,carcinoma,squamous cell carcinoma c.3227G>A p.R1076K 7:106905305-106905305 12
14 COSM97107379 NRAS skin,neck,carcinoma,squamous cell carcinoma c.35G>A p.G12D 1:114716126-114716126 12
15 COSM96979266 NCOA3 skin,neck,carcinoma,squamous cell carcinoma c.979C>T p.H327Y 20:47634062-47634062 12
16 COSM94433642 MTOR skin,neck,carcinoma,squamous cell carcinoma c.3409G>A p.E1137K 1:11212464-11212464 12
17 COSM88433397 KMT2C skin,neck,carcinoma,squamous cell carcinoma c.11659C>T p.H3887Y 7:152158874-152158874 12
18 COSM129134015 KMT2A skin,neck,carcinoma,squamous cell carcinoma c.4377T>G p.C1459W 11:118488658-118488658 12
19 COSM112988842 HRAS skin,neck,carcinoma,squamous cell carcinoma c.182A>T p.Q61L 11:533874-533874 12
20 COSM87850134 HGF skin,neck,carcinoma,squamous cell carcinoma c.974C>T p.P325L 7:81729671-81729671 12
21 COSM97161142 FUBP1 skin,neck,carcinoma,squamous cell carcinoma c.430C>T p.P144S 1:77966737-77966737 12
22 COSM90925428 FGFR3 skin,neck,carcinoma,squamous cell carcinoma c.2427A>G p.*809Wext*101 4:1807262-1807262 12
23 COSM113064666 FGFR2 skin,neck,carcinoma,squamous cell carcinoma c.2237C>T p.S746F 10:121483765-121483765 12
24 COSM96350412 EPHA7 skin,neck,carcinoma,squamous cell carcinoma c.2468G>A p.G823E 6:93254711-93254711 12
25 COSM143839996 EPHA5 skin,neck,carcinoma,squamous cell carcinoma c.2611G>A p.E871K 4:65348104-65348104 12
26 COSM90880957 EPHA3 skin,neck,carcinoma,squamous cell carcinoma c.533G>A p.G178E 3:89210239-89210239 12
27 COSM90896216 EPHA3 skin,neck,carcinoma,squamous cell carcinoma c.632T>A p.M211K 3:89210338-89210338 12
28 COSM94452739 CASP8 skin,neck,carcinoma,squamous cell carcinoma c.1508C>T p.T503I 2:201286485-201286485 12
29 COSM94447474 CASP8 skin,neck,carcinoma,squamous cell carcinoma c.1219C>T p.L407F 2:201285055-201285055 12
30 COSM88124807 ATM skin,neck,carcinoma,squamous cell carcinoma c.1009C>T p.R337C 11:108247071-108247071 12
31 COSM88887524 APC skin,neck,carcinoma,squamous cell carcinoma c.536C>T p.S179F 5:112780794-112780794 12
32 COSM86931984 AKT3 skin,neck,carcinoma,squamous cell carcinoma c.1164-1G>A p.? 1:243545598-243545598 12
33 COSM143943797 skin,neck,carcinoma,squamous cell carcinoma c.266G>A p.R89Q 17:7674220-7674220 12
34 COSM151006887 skin,neck,carcinoma,squamous cell carcinoma c.974C>T p.P325L 7:81729671-81729671 12
35 COSM87854487 skin,neck,carcinoma,squamous cell carcinoma c.1079C>T p.T360I 2:201286485-201286485 12
36 COSM90842417 skin,neck,carcinoma,squamous cell carcinoma c.11659C>T p.H3887Y 7:152158874-152158874 12
37 COSM142560281 skin,neck,carcinoma,squamous cell carcinoma c.626G>A p.R209Q 17:7674220-7674220 12
38 COSM94156150 skin,neck,carcinoma,squamous cell carcinoma c.1164-1G>A p.? 1:243545598-243545598 12
39 COSM101967270 skin,neck,carcinoma,squamous cell carcinoma c.182A>T p.Q61L 11:533874-533874 12
40 COSM96948694 skin,neck,carcinoma,squamous cell carcinoma c.1619G>A p.G540E 20:42352227-42352227 12
41 COSM144087106 skin,neck,carcinoma,squamous cell carcinoma c.266G>A p.R89Q 17:7674220-7674220 12
42 COSM125447871 skin,neck,carcinoma,squamous cell carcinoma c.2611G>A p.E871K 4:65348104-65348104 12
43 COSM96966855 skin,neck,carcinoma,squamous cell carcinoma c.1009C>T p.H337Y 20:47634062-47634062 12
44 COSM97161923 skin,neck,carcinoma,squamous cell carcinoma c.1619G>A p.G540E 20:42352227-42352227 12
45 COSM92783540 skin,neck,carcinoma,squamous cell carcinoma c.997C>T p.L333F 2:201285055-201285055 12
46 COSM133256111 skin,neck,carcinoma,squamous cell carcinoma c.1040C>T p.S347F 9:99146601-99146601 12
47 COSM144310203 skin,neck,carcinoma,squamous cell carcinoma c.626G>A p.R209Q 17:7674220-7674220 12
48 COSM96619514 skin,neck,carcinoma,squamous cell carcinoma c.1619G>A p.G540E 20:42352227-42352227 12
49 COSM92948518 skin,neck,carcinoma,squamous cell carcinoma c.5048C>T p.S1683F 9:8341168-8341168 12
50 COSM142837352 skin,neck,carcinoma,squamous cell carcinoma c.743G>A p.R248Q 17:7674220-7674220 12

Copy number variations for Squamous Cell Carcinoma, Head and Neck from CNVD:

7 (show all 42)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 33952 1 50700000 61300000 Amplification head and neck squamous cell carcinoma
2 71135 12 67700000 71500000 Amplification head and neck squamous cell carcinoma
3 78639 13 55300000 73300000 Amplification head and neck squamous cell carcinoma
4 90904 15 25700000 28100000 Amplification head and neck squamous cell carcinoma
5 93784 15 59100000 59300000 Copy number MET head and neck squamous cell carcinoma
6 118006 17 7505821 7531588 LOH TP53 head and neck squamous cell carcinoma
7 119192 18 1 7100000 Amplification head and neck squamous cell carcinoma
8 119790 18 17200000 19000000 Amplification head and neck squamous cell carcinoma
9 166134 3 1 87900000 Loss head and neck squamous cell carcinoma
10 167635 3 121900000 167600000 Gain head and neck squamous cell carcinoma
11 169556 3 142800000 148900000 Amplification head and neck squamous cell carcinoma
12 171486 3 168801287 168851758 Amplification EVI1 head and neck squamous cell carcinoma
13 171495 3 168867391 169381563 Amplification MDS1 head and neck squamous cell carcinoma
14 172487 3 182700000 187900000 Amplification RFC4 head and neck squamous cell carcinoma
15 174746 12 7773277 7793336 Deletion DLEC head and neck squamous cell carcinoma
16 179443 3 91000000 121900000 Gain head and neck squamous cell carcinoma
17 179973 4 1 50400000 Loss head and neck squamous cell carcinoma
18 204736 6 114600000 171115067 Gain head and neck squamous cell carcinoma
19 217049 7 1 159138663 Copy number head and neck squamous cell carcinoma
20 225369 7 45400000 54000000 Gain EGFR head and neck squamous cell carcinoma
21 225383 7 45400000 54000000 Amplification EGFR head and neck squamous cell carcinoma
22 225403 7 45400000 54000000 Copy number EGFR head and neck squamous cell carcinoma
23 225404 7 45400000 54000000 Copy number EGFR head and neck squamous cell carcinoma
24 225408 7 45400000 54000000 Deletion or amplification EGFR head and neck squamous cell carcinoma
25 225413 7 45400000 58000000 Amplification head and neck squamous cell carcinoma
26 226532 7 58000000 59900000 Amplification head and neck squamous cell carcinoma
27 232747 8 119200000 122500000 Gain MYC head and neck squamous cell carcinoma
28 233769 8 127300000 139900000 Gain KHDRBS3 head and neck squamous cell carcinoma
29 234876 8 139900000 146364022 Gain FAK head and neck squamous cell carcinoma
30 234895 8 139900000 146364022 Gain PTP4A3 head and neck squamous cell carcinoma
31 238011 8 28800000 45600000 Amplification head and neck squamous cell carcinoma
32 239988 8 43100000 45600000 Amplification head and neck squamous cell carcinoma
33 240109 8 45600000 146364022 Gain GAA1 head and neck squamous cell carcinoma
34 241899 8 68000000 70500000 Amplification head and neck squamous cell carcinoma
35 243677 8 86900000 101600000 Amplification RUNX1T1 head and neck squamous cell carcinoma
36 249984 9 19900000 25500000 Deletion CDKN2A head and neck squamous cell carcinoma
37 300518 11 95351087 95715992 Methylation MAML2 head and neck squamous cell carcinoma
38 300530 12 123374913 123617963 Methylation NCOR2 head and neck squamous cell carcinoma
39 300892 14 72672931 72756862 Methylation PSEN1 head and neck squamous cell carcinoma
40 300893 14 72811670 72995039 Methylation NUMB head and neck squamous cell carcinoma
41 302931 19 45863651 45888396 Methylation NUMBL head and neck squamous cell carcinoma
42 303261 20 10566331 10602694 Methylation JAG1 head and neck squamous cell carcinoma
Sources

Expression for Squamous Cell Carcinoma, Head and Neck

About this section
LifeMap Discovery
Genes differentially expressed in tissues of Squamous Cell Carcinoma, Head and Neck patients vs. healthy controls: 35 (show all 15)
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 MMP1 matrix metallopeptidase 1 Head Mesenchyme + 5.25 0.000
2 TMPRSS11B transmembrane protease, serine 11B Head Mesenchyme - 4.81 0.000
3 CRISP3 cysteine-rich secretory protein 3 Head Mesenchyme - 4.48 0.000
4 MAL mal, T-cell differentiation protein Head Mesenchyme - 4.39 0.000
5 INHBA inhibin, beta A Head Mesenchyme + 4.13 0.000
6 CRNN cornulin Head Mesenchyme - 4.00 0.000
7 KRT17 keratin 17, type I Head Mesenchyme + 3.94 0.000
8 KRT4 keratin 4, type II Head Mesenchyme - 3.41 0.000
9 PTHLH parathyroid hormone-like hormone Head Mesenchyme + 3.36 0.000
10 CTHRC1 collagen triple helix repeat containing 1 Head Mesenchyme + 3.32 0.000
11 CLCA4 chloride channel accessory 4 Head Mesenchyme - 3.31 0.000
12 WDR72 WD repeat domain 72 Head Mesenchyme + 3.23 0.000
13 MMP10 matrix metallopeptidase 10 Head Mesenchyme + 3.14 0.001
14 TGM3 transglutaminase 3 Head Mesenchyme - 3.08 0.000
15 GBP1 guanylate binding protein 1, interferon-inducible Head Mesenchyme + 3.06 0.000
Search GEO for disease gene expression data for Squamous Cell Carcinoma, Head and Neck.
Sources

Pathways for Squamous Cell Carcinoma, Head and Neck

About this section

Pathways related to Squamous Cell Carcinoma, Head and Neck according to GeneCards Suite gene sharing:

(show top 50) (show all 84)
# Super pathways Score Top Affiliating Genes
1
ERK Signaling 63
Show member pathways
 13.88 TP53 TNFRSF10B SMAD4 PTEN MAP2K2 HRAS
2
TGF-Beta Pathway 63
Show member pathways
 13.6 TP53 TNFRSF10B SMAD4 PIK3CA MAP2K2 HRAS
3
Toll-like Receptor Signaling Pathway 1 36
Show member pathways
 13.16 TP53 SMAD4 PIK3CA MIR98 MAP2K2 HRAS
4
Phospholipase-C Pathway 63
Show member pathways
 13.12 TP53 PTEN MAP2K2 HRAS GNAS FGFR3
5
PI3K-Akt signaling pathway 36
Show member pathways
 13.04 TP53 PTEN PIK3CA MAP2K2 HRAS GNAS
6
TNFR1 Pathway 63
Show member pathways
 13 TP53 TNFRSF10B PTEN PIK3CA MAP2K2 HRAS
7
NFAT and Cardiac Hypertrophy 63
Show member pathways
 12.92 PTEN PIK3CA MAP2K2 HRAS GNAS FGFR3
8
Endometrial cancer 36
Show member pathways
 12.9 TP53 SMAD4 PTEN PIK3CA MAP2K2 HRAS
9
Apoptosis Modulation and Signaling 1
Show member pathways
 12.85 TP53 TNFRSF10B PIK3CA MAP2K2 HRAS
10
Common Cytokine Receptor Gamma-Chain Family Signaling Pathways 64
Show member pathways
 12.82 PTEN PIK3CA MAP2K2 HRAS BRAF
11
MAPK signaling pathway 36 1
12.81 TP53 MAP2K2 HRAS FGFR3 BRAF
12
Ras signaling pathway 36
Show member pathways
 12.8 PIK3CA MAP2K2 HRAS GNAS FGFR3 BRAF
13
Downstream signaling events of B Cell Receptor (BCR) 65
Show member pathways
 12.77 TP53 PTEN PIK3CA HRAS FGFR3
14
Development HGF signaling pathway 22
Show member pathways
 12.77 TP53 PTEN PIK3CA MAP2K2 HRAS BRAF
15
Regulation of actin cytoskeleton 36 1
12.68 PIK3CA MAP2K2 HRAS FGFR3 BRAF
16
Glioma 36
Show member pathways
 12.66 TP53 PTEN PIK3CA MAP2K2 HRAS GNAS
17
Gastric cancer 36
Show member pathways
 12.64 TP53 SMAD4 PTEN PIK3CA NFE2L2 MAP2K2
18
ErbB signaling pathway 1 36
Show member pathways
 12.59 TP53 PTEN PIK3CA MAP2K2 HRAS FGFR3
19
Immune response Role of DAP12 receptors in NK cells 22
Show member pathways
 12.58 TNFRSF10B PIK3CA MAP2K2 HRAS BRAF
20
Development ERBB-family signaling 22
Show member pathways
 12.58 TP53 PIK3CA MAP2K2 HRAS BRAF
21
Apoptosis Pathway 70
Show member pathways
 12.51 TP53 PIK3CA MAP2K2 HRAS FGFR3
22
B cell receptor signaling pathway (KEGG) 1
Show member pathways
 12.47 PTEN PIK3CA MAP2K2 HRAS BRAF
23
Development IGF-1 receptor signaling 22
Show member pathways
 12.46 TP53 PTEN PIK3CA MAP2K2 HRAS
24
Phospholipase D signaling pathway 36
Show member pathways
 12.45 PIK3CA MAP2K2 HRAS GNAS
25
Development FGFR signaling pathway 22
Show member pathways
 12.45 PIK3CA MAP2K2 HRAS FGFR3
26
Development VEGF signaling via VEGFR2 - generic cascades 22
Show member pathways
 12.44 PIK3CA MAP2K2 HRAS BRAF
27
G-protein signaling RAC1 in cellular process 22
Show member pathways
 12.44 PIK3CA MAP2K2 HRAS FGFR3 BRAF
28
DNA Damage Response 1
Show member pathways
 12.42 TP53 TNFRSF10B PTEN MIR210
29
G-protein signaling G-Protein alpha-i signaling cascades 22
Show member pathways
 12.42 MAP2K2 HRAS GNAS BRAF
30
mTOR signaling pathway (KEGG) 64
Show member pathways
 12.41 TP53 PTEN PIK3CA MAP2K2 HRAS FGFR3
31
cAMP signaling pathway 36
12.38 PIK3CA MAP2K2 GNAS BRAF
32
Toll Comparative Pathway 63
Show member pathways
 12.38 TP53 PIK3CA MAP2K2 HRAS GNAS
33
Pathways in cancer 36
12.38 TP53 SMAD4 PTEN PIK3CA NFE2L2 MAP2K2
34
B Cell Receptor Signaling Pathway (sino) 66
Show member pathways
 12.37 PTEN PIK3CA MAP2K2 HRAS
35
Development Ligand-independent activation of ESR1 and ESR2 22
Show member pathways
 12.37 PIK3CA MAP2K2 HRAS GNAS
36
Human T-cell leukemia virus 1 infection 36
12.35 TP53 SMAD4 PTEN PIK3CA MAP2K2 HRAS
37
Signaling by FGFR2 65
Show member pathways
 12.32 PIK3CA HRAS FGFR3 BRAF
38
Proteoglycans in cancer 36
12.3 TP53 PIK3CA MIR21 MAP2K2 HRAS BRAF
39
VEGF Signaling Pathway 66 60
Show member pathways
 12.29 PTEN MAP2K2 HRAS FGFR3
40
G-protein signaling Ras family GTPases in kinase cascades (scheme) 22
Show member pathways
 12.27 TP53 MAP2K2 HRAS BRAF
41
Long-term potentiation 36
Show member pathways
 12.25 MAP2K2 HRAS GNAS BRAF
42
Colorectal Cancer Metastasis 63
12.25 TP53 SMAD4 MAP2K2 GNAS BRAF
43
EGF/EGFR Signaling Pathway 1
12.24 PTEN MAP2K2 HRAS BRAF
44
Kit receptor signaling pathway 1
Show member pathways
 12.23 PTEN PIK3CA MAP2K2 HRAS
45
mTOR Pathway 70
Show member pathways
 12.22 TP53 PIK3CA MAP2K2 HRAS BRAF
46
Integrated Breast Cancer Pathway 1
12.21 TP53 SMAD4 PTEN BRAF
47
Cellular senescence (KEGG) 36
12.21 TP53 PTEN PIK3CA MAP2K2 HRAS
48
NGF Pathway 63
Show member pathways
 12.2 TP53 MAP2K2 HRAS BRAF
49
MAPK Signaling: Mitogen Stimulation Pathway 64
Show member pathways
 12.19 TP53 PTEN PIK3CA MAP2K2 HRAS FGFR3
50
Development EGFR signaling via small GTPases 22
Show member pathways
 12.18 PTEN PIK3CA MAP2K2 HRAS GNAS
Sources

GO Terms for Squamous Cell Carcinoma, Head and Neck

About this section

Biological processes related to Squamous Cell Carcinoma, Head and Neck according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 gene silencing by miRNA GO:0035195 9.86 MIR98 MIR210 MIR21 MIR205
2 MAPK cascade GO:0000165 9.85 MAP2K2 HRAS FGFR3 BRAF
3 positive regulation of gene expression GO:0010628 9.8 TP53 PTEN NFE2L2 MIR21 HRAS BRAF
4 positive regulation of apoptotic process GO:0043065 9.77 TP53 TNFRSF10B PTEN MIR21 ING3
5 negative regulation of ERK1 and ERK2 cascade GO:0070373 9.7 SMAD4 PTEN MIR21
6 cellular response to drug GO:0035690 9.67 TP53 NFE2L2 BRAF
7 positive regulation of osteoblast differentiation GO:0045669 9.65 MIR210 MIR21 GNAS
8 negative regulation of cell proliferation GO:0008285 9.63 TP53 SMAD4 PTEN MIR21 ING1 HRAS
9 miRNA mediated inhibition of translation GO:0035278 9.56 MIR98 MIR210 MIR21 MIR205
10 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.54 TP53 MAP2K2
11 positive regulation of metalloendopeptidase activity GO:1904685 9.51 MIR21 MIR205
12 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.46 MIR210 MIR21
13 positive regulation of transcription from RNA polymerase II promoter in response to stress GO:0036003 9.43 TP53 NFE2L2
14 positive regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061419 9.4 TP53 NFE2L2
15 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.35 PTEN MIR21 HRAS FGFR3 BRAF
16 regulation of axon regeneration GO:0048679 8.8 PTEN MAP2K2 BRAF

Molecular functions related to Squamous Cell Carcinoma, Head and Neck according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.26 MIR98 MIR210 MIR21 MIR205
2 transcription cofactor binding GO:0001221 8.62 TP53 NFE2L2
Sources

Sources for Squamous Cell Carcinoma, Head and Neck

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....